Biotech Lab 4.0
Vaccine development by design
A revolutionary way to accelerate, control and implement processes in real time by creating intelligent networks of equipment and open data systems that govern each other.
AchilleS Vaccines Biotech Lab 4.0 is a new model of early stage development for new biopharmaceutical products, particularly those containing, or consisting of, recombinant proteins (e.g. vaccines, immuno-therapeutics, ), and a new model of pre-clinical R&D.
AchilleS Vaccines exploits integrated technological platforms to identify, select and develop future approaches to deliver effective products.
They Talk About Us
Siena, 19 February 2021 – Diesse Diagnostica Senese and AchilleS Vaccines today announced the signing of a strategic agreement under which Diesse develops diagnostics tests
Innovative monoclonal antibody developed by AchilleS can be administered intramuscularly, broadening access to COVID-19 treatment; Industrial development of Monoclonal antibody completed today and will
In Europe, the fight against the Covid-19 pandemic was mainly focused on developing a vast number of vaccines through the use of different technologies. But